Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
about
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapyThienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.Cangrelor for the management and prevention of arterial thrombosis.Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor.
P2860
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Potentiation of clopidogrel ac ...... aggregation after clopidogrel.
@en
Potentiation of clopidogrel ac ...... aggregation after clopidogrel.
@nl
type
label
Potentiation of clopidogrel ac ...... aggregation after clopidogrel.
@en
Potentiation of clopidogrel ac ...... aggregation after clopidogrel.
@nl
prefLabel
Potentiation of clopidogrel ac ...... aggregation after clopidogrel.
@en
Potentiation of clopidogrel ac ...... aggregation after clopidogrel.
@nl
P2093
P2860
P1476
Potentiation of clopidogrel ac ...... aggregation after clopidogrel
@en
P2093
J A Jakubowski
P2860
P304
P356
10.1111/J.1538-7836.2010.03925.X
P577
2010-05-21T00:00:00Z